Albena Zlatareva

Prof. Dr. Albena Zlatareva

orcid

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2017 in Acta Medica Bulgarica
Verified
Journal Article
Open access
PDF file
AZAlbena Zlatareva
Albena Zlatareva
KKK. Krahtova
K. Krahtova
TKTch. Kazak
Tch. Kazak
Cancer as a financial value is one of the most expensive diseases. Costs, including the cost of new cancer drugs, are increasing at an unsustainable rate, threatening the permanent access of patients to treatment. Prices for new treatments against cancer have doubled over the past 10 years and now are usually between USD 6000 and USD 10,000 per month, this increase is often not correlated with reimbursement and implemented public health benefits. According to various authors, these results lead to debate whether the cost differences between EU countries and the US for the treatment of oncologic diseases are transformed into improved outcomes for patients, and must also take into account key factors such as lifestyle, late diagnosis, and management approach for treatment, reimbursement of oncology treatment and control of various institutions on spending.

3 August 2024 in Hemato
Verified
Journal Article
Open access
PDF file
VSVelizar Shivarov
Velizar Shivarov
DGDenitsa Grigorova
Denitsa Grigorova
MNMira Nedeva
Mira Nedeva
TMTodor Milkov
Todor Milkov
AZAlbena Zlatareva
Albena Zlatareva
angel yordanovangel yordanov
angel yordanov
Background: In the last two decades, tyrosine kinase inhibitors (TKIs) and advances in molecular diagnostics have revolutionized management and long-term clinical outcomes in chronic myeloid leukemia (CML). Real-world data from different countries allow for the identification of country-specific issues in the clinical management and development of specific plans for improvement. Here, we aimed to analyze the trend in overall survival in Bulgarian CML patients since 2000. Methods: We retrieved publicly available Bulgarian CML data from several sources such as the Bulgarian National Cancer Registry, Bulgarian National Statistical Institute, and National Health Insurance Fund since 2000. We used the retrieved data of a total of 1513 Bulgarian CML patients to describe the trends in overall survival (OS), conditional overall survival, life expectancy, and life years lost over five time periods. We also described the trends in healthcare expenditures for TKIs and CML patients’ coverage with TKIs since 2014. Results: In both uni- and multivariate models, we found a constant increase in OS over the three 5-year periods until 2014. The period 2015–2019 was not associated with an additional increase in OS. Identical dynamics in the improvement in life expectancy (LE) and in life years lost (LYLs) was observed. Additionally, conditional 5-year survival did not improve during 2015–2019 in comparison to 2010–2014. Population-level data did not show consistent changes in the documented number of deaths due to CML since 2013. The period after 2013 is marked by a constant increase in the annual expenditures for TKIs, reaching to about 2.0 EUR/capita. The number of patients who received at least one TKI also increased during that period. Conclusions: After the initial significant improvement in the clinical outcomes for Bulgarian CML patients until 2014, subsequent periods did not bring further benefit in spite of the improved coverage with second- and third-line TKIs. Multiple factors may contribute to these suboptimal outcomes. Therefore, one can propose several additional measures at the country level, which could lead to additional improvement in the OS of Bulgarian CML patients.

31 October 2021 in Folia Medica
Verified
Journal Article
Open access
PDF file
BBBranimir Brankov
Branimir Brankov
AZAlbena Zlatareva
Albena Zlatareva
Aim: The objectives of our study were to establish the extent to which medical professionals are willing to upgrade their skills, to find out whether they have to resort often in their daily work to the support of colleagues in matters related to pharmaceutical policy, and to find out if they attend any forms of continuing education and whether such forms are available at their workplaces. The study also aimed to establish what web-based forms of continuous education the graduated medical professionals in Bulgaria, Croatia, and Slovenia know and consider to be up-to-date and adequate to their needs for specialised training programmes which ensure that their knowledge will be adequate to the constantly evolving environment in the area of pharmaceutical policy and pharmaceutical regulation. Materials and methods: A survey was carried out among a representative sample drawn from three Balkan countries: Bulgaria, Croatia, and Slovenia. The survey was based on voluntary participation and relied on the ‘snowballing’ technique in order to recruit respondents and disseminate questionnaires. Results: The results from the study demonstrate that the respondents are willing to, and are aware that they should, join forms of continuing education in the area of pharmaceutical policy since some of them encounter certain challenges related to the level of their knowledge in this domain, and that the deployment of specialised online programmes and other activities (such as workshops, conferences, etc.) for professional qualification of employees will certainly contribute to the enhancement of their qualification and to the improvement of the health services provided to citizens. Conclusions: To keep in pace with modern trends in the area of postgraduate education, the medical universities which are most trusted by the respondents from the three countries included in survey as well as the career development services providers which offer postgraduate training courses should focus on the development and implementation of innovative forms of web-based postgraduate/upskilling education in the area of pharmaceutical policy to ensure that more potential learners can join and update their understanding of this dynamic and rapidly evolving area of scientific knowledge.

7 June 2024 in Pharmacia
Verified
Journal Article
Open access
PDF file
VGVioleta Getova-Kolarova
Violeta Getova-Kolarova
AZAlbena Zlatareva
Albena Zlatareva
IKIvo Kumanov
Ivo Kumanov
This study delves into the intricate interplay between trust in personal doctors (GPs), sources of information about recommended vaccines, and the willingness to vaccinate against human papillomavirus (HPV) and other recommended vaccines. The analysis revealed a positive and statistically significant correlation between HPV awareness and the willingness to vaccinate. Notably, awareness concerning HPV is high, with 35.6% of all respondents expressing readiness to receive the HPV vaccine. The study identified the personal doctor as the predominant source of vaccine-related information. The identified correlations underscore the influence of medical professionals in guiding vaccine uptake choices and the necessity for targeted communication strategies aimed at enhancing vaccine acceptance.

2 August 2024 in Pharmacia
Verified
Journal Article
Open access
PDF file
VGVioleta Getova-Kolarova
Violeta Getova-Kolarova
AZAlbena Zlatareva
Albena Zlatareva
IKIvo Kumanov
Ivo Kumanov
This is a national, qualitative and quantitative investigation involving 600 participants which employed interviews and standardized self-administered questionnaires to assess participants’ HPV vaccine knowledge and their inclination to vaccinate. The results of the study underscore the pivotal influence of informed awareness campaigns in shaping vaccination behaviours and stress the imperative of tailored educational strategies to augment vaccine uptake. All respondents shared as a main concern insufficient information about the vaccine and low degree of familiarity. An inquiry into the correlation between having children and HPV vaccine knowledge revealed that individuals with children under 16 years old manifested heightened levels of HPV vaccine knowledge. The outcomes suggest that individuals with young children are more inclined to harbour comprehensive HPV vaccine knowledge.